Shots:

• The NDA submission is based on two P-III studies (COUGH-1 & -2) involves assessing gefapixant (45/15mg- bid) vs PBO in 2-044 patients with RCC & UCC
• In both the studies- gefapixant resulted in the reduction of in 24hrs.-cough frequency @12 & 24wks respectively. Data were presented at ERS 2020
• Gefapixant is a selective P2X3 receptor antagonist for the potential treatment of refractory or unexplained chronic cough. The anticipated PDUFA date is Dec 21- 2021

 ­ Ref: Businesswire | Image: Merck